Biotek-snakken — Oktober 2020
-
Lyder fornuftigt....lad høre om du finder andet interessant
Jeg har for nylig taget en portion Deinove SA (handler i EUR) som er et mix mellem antibiotics og bioactives. Deres vigtigste projekt er i fase 2 (DNV3837) som er under fast track (men også forsinket af covid). Studie kører i US. http://www.deinove.com/en/investor-room/documentation-center/investors-slide-deck -
Dette link giver et billede af hvad der er i gang af udvikling i antibiotics - muligt at filtrere på (ikke alt er noteret desværre) https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2014/antibiotics-currently-in-clinical-development.
-
Nogen der ved hvornår handlen med curasight åbner? Den kommer på børsen i dag, men kan ikke se den på nordnet
-
For biotektosser: https://www.proinvestor.com/boards/87389/For-biotektosser
-
Cantargia - Tumor shrinkage in NSCLC combination
6 of 9 evaluable patients with metastatic NSCLC showed objective response incl 1 compl response
The complete response has lasted more than 1 year
Video clip :https://twitter.com/RS6HK605/status/1314109285958324225
-
ArcticZymes has entered into an agreement with Simcere Diagnostics to supply its HL-SAN product for Simcere’s metagenomics sequencing tests
Tromsø, 08 October, 2020: ArcticZymes AS, a subsidiary of ArcticZymes Technologies ASA (OSE:AZT), announces that it has entered into a supply and distribution agreement with precision medicine company Jiangsu Simcere Diagnostics, Nanjing, China for the supply of Heat-Labile Salt Active Nuclease (HL-SAN) to be used in the development and manufacturing
-
ArcticZymes Technologies ASA, CEO, Jethro Holter said: “We look forward to supporting Simcere in the development and future commercialization of their innovative sequencing assays as well as other future technologies. This is just the beginning of a long-term relationship together where ArcticZymes’ novel enzyme technologies and scientific competence will aid Simcere Diagnostics in marketing best in class sequencing technologies. The agreement marks the first step for ArcticZymes in China.
-
Simcere Diagnostics CEO, Yong Ren said:
“Simcere Diagnostics is excited to collaborate with ArcticZymes AS. This global collaboration not only helps Simcere in the development and commercialization of its metagenomic products, it also provides our friend ArcticZymes with a market penetration opportunity to the Chinese market. We plan to work closely in the future to explore additional means to strengthen our partnership and achieve additional penetration in China.” -
HL-SAN is a critical component of Simcere Diagnostics’ infectious disease metagenomic assays. In particular, the nuclease supplied by ArcticZymes plays a key role in the removal of host DNA from the sample. This results in a streamlined and efficient sample preparation process that reduces background noise from the assay. Metagenomic assays are extremely sensitive to competing background noise. Fortunately, HL-SAN’s unique capability to interact with salt provides Simcere the best host DNA remov
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind